Clinical trial · no report yet · Phase 3
IMvigor011
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
- NCT04660344 ↗
- Active not recruiting
- Hoffmann-La Roche
- 300 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 189 | |
| YouTube | 57 | |
| Podcasts | 51 | |
| X videos | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Double-blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-risk Muscle-invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Muscle-invasive Bladder Cancer
- Interventions
- Atezolizumab; Placebo; Signatera
- Arms
- Arm A: Atezolizumab · Experimental
- Arm B: Placebo · Placebo comparator
- Arm C: Surveillance Follow-Up · Experimental
- Enrollment
- 761
- Primary outcomes
- INV-assessed Disease-free Survival (DFS)
- Sponsor
- Hoffmann-La Roche with Natera, Inc.
- Start
- May 3, 2021
- Primary completion
- Jun 15, 2025
- Results posted
- Yes
- Registry record
- NCT04660344 · updated Sep 28, 2026
Publications
linked from the registry- Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, Bjerggaard Jensen J, Makaroff L, Jiang S, Ku JH, Park SH, Reig Torras O, Ye D, Maruzzo M, Necchi A, Morales-Barrera R, Giunta EF, Lee JL, Tortora G, Urun Y, Dolowy L, Erdem D, Pinto A, Grando F, Zou W, Assaf ZJ, Vuky J, Degaonkar V, Steinberg EE, Bellmunt J, Gschwend JE; IMvigor011 Investigators. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. N Engl J Med. 2025 Dec 18;393(24):2395-2408. doi: 10.1056/NEJMoa2511885. Epub 2025 Oct 20. PubMed 41124204
- Jackson-Spence F, Toms C, O'Mahony LF, Choy J, Flanders L, Szabados B, Powles T. IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future Oncol. 2023 Mar;19(7):509-515. doi: 10.2217/fon-2022-0868. Epub 2023 Apr 21. PubMed 37082935